TNFRSF8 and Hodgkins lymphoma: The advent of effective, rationally designed, targeted antibody-drug conjugates such as gentuzumab ozogamicin targeting CD33 for acute myeloid leukemia [16], trastuzumab-emtansine (TDM-1, Kadcyla) targeting Her2 for breast cancer [17], and brentuximab vedotin (Adcetris) targeting CD30 for Hodgkin's lymphoma and for systemic anaplastic large cell lymphoma [18] has stimulated a search for novel drug targets that provide new opportunities and paradigms for immunotherapeutic intervention [19].